Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Overview:Chemotherapy Induced Peripheral Neuropathy Therapeutics Drugs,Companies,Market Size, Shares, New Study Pipeline Review,H2 2016

Sunday, October 2, 2016 23:20
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Chemotherapy Induced Peripheral Neuropathy Pipeline Review, H2 2016

Global Markets Direct’s, Chemotherapy Induced Peripheral Neuropathy   - Pipeline Review, H2 2016′, provides an overview of the Chemotherapy Induced Peripheral Neuropathy   pipeline landscape.

 

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy  and features dormant and discontinued projects.

 

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

 

Complete report on Chemotherapy Induced Peripheral Neuropathy  - Pipeline Review, H2 2016 addition with 44 market data tables and 14 figures, spread across 128 pages is  http://www.rnrmarketresearch.com/chemotherapy-induced-peripheral-neuropathy-pipeline-review-h2-2016-market-report.html

 

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis

 

Drugs Profile Discussed in this Research:

(amitriptyline + ketamine hydrochloride), AM-1710 , AXPN-02, BR-297, cannabidiol, dimiracetam Drugs for Peripheral Neuropathy, DX-0332, E-2072 , HM-01,, ketoprofen KP-544 , KRN-5500, LM11A-31BHS, Lpathomab, MR-309, NB-2111 , NRX-2922 , NT-24336, PAN-811 , PGN-503, piclidenoson, pirenzepine hydrochloride , PP-095, Q-201, Small Molecule for Pain, Neuropathy, Small Molecule to Inhibit FAAH for Chemotherapy Induced Peripheral Neuropathy, Small Molecules to Agonize Adenosine A3 Receptor for Chemotherapy Induced Peripheral Neuropathy , Small Molecules to Inhibit FKBP52 for Chemotherapy Induced Peripheral Neuropathy, Small Molecules to Inhibit Hsp90 for Amyotrophic Lateral Sclerosis and Peripheral Neuropathy, SPI-205, Tetrodotoxin, U-2902, XT-150

Companies Discussed/Mentioned in this Research:

Achelios Therapeutics, Advinus Therapeutics Ltd, Amplyx Pharmaceuticals, Can-Fite BioPharma Ltd., DermaXon, Eisai Co., Ltd., Immune Pharmaceuticals Inc.,  INSYS Therapeutics, Inc., KPI Therapeutics, Inc., Krenitsky Pharmaceuticals Inc., Laboratorios Del Dr. Esteve S.A. Lpath, Inc., MAKScientific, LLC, Metys Pharmaceuticals AG, Midatech Pharma US Inc., Nemus Bioscience, Inc., Neurocentrx Pharma Ltd., Panacea Pharmaceuticals, Inc.,  PeriphaGen, Inc., PharmatrophiX, Inc., PledPharma AB, Sova Pharmaceuticals, Inc., Spectrum Pharmaceuticals, Inc., Virobay Inc., WEX Pharmaceuticals Inc.,

Inquire before buying for this report

http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=696571(This is a premium report price at US$2000 for a single user PDF license).

Scope:                                                       

  • The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy  
  • The report reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RandD brief, licensing and collaboration details and other developmental activities
  • The report reviews key players involved Chemotherapy Induced Peripheral Neuropathy  therapeutics and enlists all their major and minor projects
  • The report assesses Chemotherapy Induced Peripheral Neuropathy   therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy  

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective RandD strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy  
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy   pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

About Us:

RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market 

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.